Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
empagliflozin (BI-10773)
print preview
bookmark
share with colleague
General Information
Company
Boehringer Ingelheim GmbH
Description
Sodium-glucose cotransporter 2 (SGLT2) inhibitor
Molecular Target
Sodium-glucose cotransporter 2 (SGLT2)
Mechanism of Action
Sodium-glucose cotransporter 2 (SGLT2) inhibitor
Latest Stage of Development
Registration
Indication
Diabetes
Partner
Eli Lilly and Co.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy
General Information